Betaine increases mitochondrial content and improves hepatic lipid metabolism

Zhang, Lifang; Qi, Yilin; Aluo, Zhier; Liu, Siqi; Zhang, Zhiwang; Zhou, Lei

doi:10.1039/c8fo02004c

Cited by 78 publications

(54 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Enhanced FTO expression can increase expression of lipogenic genes, containing fatty acid synthase (FASN), stearoyl-CoA desaturase (SCD) and monoacylglycerol O-acyltransferase 1 (MOGAT1), and intracellular TG level in HepG2 cells [101], which finally promotes hepatic fat accumulation. Meanwhile, these effects can be effectively reversed by betaine (a methyl donor) [101,103]. Increased FTO levels are also highly involved in hepatic oxidative stress and lipid deposition which participate in the process of NAFLD [99].…”

Section: A Methylation and Nafldmentioning

confidence: 99%

RNA N6-methyladenosine: a promising molecular target in metabolic diseases

Wang

Huang

et al. 2020

Cell Biosci

View full text Add to dashboard Cite

N6-methyladenosine is a prevalent and abundant transcriptome modification, and its methylation regulates the various aspects of RNAs, including transcription, translation, processing and metabolism. The methylation of N6-methyladenosine is highly associated with numerous cellular processes, which plays important roles in the development of physiological process and diseases. The high prevalence of metabolic diseases poses a serious threat to human health, but its pathological mechanisms remain poorly understood. Recent studies have reported that the progression of metabolic diseases is closely related to the expression of RNA N6-methyladenosine modification. In this review, we aim to summarize the biological and clinical significance of RNA N6-methyladenosine modification in metabolic diseases, including obesity, type 2 diabetes, non-alcoholic fatty liver disease, hypertension, cardiovascular diseases, osteoporosis and immune-related metabolic diseases.

show abstract

Section: A Methylation and Nafldmentioning

confidence: 99%

RNA N6-methyladenosine: a promising molecular target in metabolic diseases

Wang

Huang

et al. 2020

Cell Biosci

View full text Add to dashboard Cite

show abstract

“…Li co-cultured betaine with high glucose induced mouse mesangial cells and found that betaine could inhibit cell proliferation and extracellular matrix deposition via regulating regulation of the Akt/Erk1/2/p38 MAPK signaling pathway [37]. Another data indicated that betaine could ease hepatic fat accumulation and promoted mitochondrial content and activity [38]. These evidences suggested that betaine was involved in the regulation of lipid and energy metabolism, which were key effectors in the pathogenesis of T2D and CAD.…”

Section: Discussionmentioning

confidence: 97%

Low serum betaine levels as a potential biomarker for type 2 diabetes mellitus in patients with coronary artery disease

Guo

Qiu

Zhu

et al. 2020

Preprint

View full text Add to dashboard Cite

Background Dietary betaine intake was reported to associate with improved metabolic profile in type 2 diabetes (T2D). However, the role of circulating betaine in coronary artery disease (CAD) patients with T2D is still unknown. This study aimed to investigate the potential role of serum betaine as a potential biomarker for T2D risk in CAD patients. Methods Total 307 subjects were enrolled with 165 CAD patients (57 with T2D and 108 without) and 142 age and sex matched controls (CON). Fasting serum betaine were detected using liquid chromatography tandem mass spectrometry. Results Serum betaine were lower in simple CAD patients compared with healthy controls, and were further decreased in CAD patients with T2D. Betaine was inversely associated with fasting glucose. Subjects in the highest betaine tertile group had lower triglycerides, total cholesterol and low-density lipoprotein as well was lower percentage of CAD and T2D. Increased betaine in CAD was independently associated with low risk of T2D. Furthermore, betaine was a potential diagnostic marker in distinguishing simple CAD from CAD with T2D. Conclusion Low levels of betaine are associated with increased risk of CAD and T2D in CAD, and could be a biomarker for predicting T2D in CAD.

show abstract

“…Betaine could inhibit cell proliferation and extracellular matrix deposition under high glucose stimulation via regulating the Akt/Erk1/2/p38 MAPK signaling pathway [ 34 ]. Results of Zhang et al’s study indicated that betaine could ease hepatic fat accumulation and promoted mitochondrial content and activity [ 35 ]. These evidences suggested that betaine was involved in the lipid homeostasis and energy metabolism, which were key effectors in the pathogenesis of diabetes and CAD.…”

Section: Discussionmentioning

confidence: 99%

Association between plasma betaine levels and dysglycemia in patients with coronary artery disease

et al. 2020

View full text Add to dashboard Cite

Background: Dietary betaine intake was reported to associate with favorable profile of metabolic disorders. However, the role of circulating betaine in coronary artery disease (CAD) patients with dysglycemia is still unknown. This study aimed to investigate the potential associations between plasma betaine levels and dysglycemia in CAD patients. Methods: Total 307 subjects were enrolled in this study with 165 CAD patients (57 with dysglycemia and 108 with normal glycemia) and 142 age and sex matched controls (CON). Fasting plasma betaine were detected using liquid chromatography tandem mass spectrometry. Results: Plasma betaine were lower in normal glycemia CAD patients (28.29(22.38-35.73) μM) compared with healthy controls (29.75(25.32-39.15) μM), and were further decreased in CAD patients with dysglycemia (24.14(20.84-30.76) μM, p < 0.01). Betaine levels were inversely correlated with fasting glucose, glycated hemoglobin%, diastolic blood pressure, triglyceride and alanine aminotransferase levels (all, p ≤ 0.05). Subjects in the highest betaine tertile group had lowest frequency of CAD and dysglycemia (all, p < 0.01). Increased betaine levels were independently associated with low risk of dysglycemia in CAD after adjustment for multiple traditional risk factors (OR = 0.04, 95%CI: 0-0.37, p = 0.01). Furthermore, betaine had good performance at distinguishing CAD with dysglycemia from normal glycemia CAD (AUC = 0.62, p < 0.01). Conclusion: Plasma betaine levels are independently and inversely associated with dysglycemia in CAD after adjustment for multiple factors, and may be useful for risk stratification of dysglycemia in CAD.

show abstract

Betaine increases mitochondrial content and improves hepatic lipid metabolism

Abstract: Betaine enhances both mitochondrial content and ATP levels.

Cited by 78 publications

References 26 publications

RNA N6-methyladenosine: a promising molecular target in metabolic diseases

RNA N6-methyladenosine: a promising molecular target in metabolic diseases

Low serum betaine levels as a potential biomarker for type 2 diabetes mellitus in patients with coronary artery disease

Association between plasma betaine levels and dysglycemia in patients with coronary artery disease

Contact Info

Product

Resources

About